Vyondys 53

Drug Sarepta Therapeutics, Inc.
Total Payments
$2.8M
Transactions
166
Doctors
6
Companies
1

Payment Trends by Year

Year Amount Transactions Doctors
2023 $11,802 5 4
2022 $5,313 1 0
2020 $2.8M 160 2

Payments by Nature

Nature of Payment Amount Transactions Share
Unspecified $2.8M 161 99.9%
Consulting Fee $1,800 1 0.1%
Food and Beverage $71.13 4 0.0%

Payments by Type

Research
$2.8M
161 transactions
General
$1,871
5 transactions

Research Studies & Clinical Trials

Study Name Sponsor Amount Doctors
4045-301 Sarepta Therapeutics, Inc. $2.8M 1
4053-101 Sarepta Therapeutics, Inc. $17,043 0

Top Doctors Receiving Payments for Vyondys 53

Doctor Specialty Location Total Records
Unknown Minneapolis, MN $2.8M 159
, MD Nephrology Miami, FL $3,000 2
, MD Nephrology New York, NY $1,800 1
, MD Neurodevelopmental Disabilities San Antonio, TX $17.79 1
, MD Neurology with Special Qualifications in Child Neurology San Antonio, TX $17.78 1
, MD Neurology with Special Qualifications in Child Neurology San Antonio, TX $17.78 1
, M.D Student in an Organized Health Care Education/Training Program San Antonio, TX $17.78 1

About Vyondys 53

Vyondys 53 is a drug associated with $2.8M in payments to 6 healthcare providers, recorded across 166 transactions in the CMS Open Payments database. The primary manufacturer is Sarepta Therapeutics, Inc..

Payment data is available from 2020 to 2023. In 2023, $11,802 was paid across 5 transactions to 4 doctors.

The most common payment nature for Vyondys 53 is "Unspecified" ($2.8M, 99.9% of total).

Vyondys 53 is associated with 2 research studies, including "4045-301" ($2.8M).